Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression

Introduction: Infections are common following stroke and adversely affect outcome. Cellular immune suppression associated with acute stroke may increase susceptibility to infection. Cytokines are important contributors to both stroke pathology and the response to infection. Since interleukin (IL)-1 blockade is a candidate treatment for cerebral ischemia, we examined whether administration of interleukin-1 receptor antagonist (IL-1Ra) to patients with acute stroke affected innate cellular immune responses in a phase II placebo-controlled trial. Methods: Venous blood samples were taken prior to treatment initiation, at 24 h and 5 to 7d. Blood was also drawn from stroke-free controls. Lipopolysaccharide (LPS) stimulation of whole-blood cultures assessed the potential of leukocytes to produce cytokines. Results: Induction of tumor necrosis factor (TNF)-alpha, IL-1 beta, IL-6, IL-8 and IL-10 by LPS was significantly reduced in patients at admission, compared to controls. At 24 h, cytokine induction remained suppressed in the placebo group. In contrast, for patients treated with IL-1Ra, induction of TNF-alpha. IL-6 and IL-10 was similar to controls and IL-1 beta induction was significantly greater than in the placebo group. At 5 to 7d, TNF-alpha and IL-1 beta induction remained suppressed only in the placebo group (p < 0.05). Plasma cortisol concentrations, elevated at admission in patients compared to controls, were substantially reduced at 24 h in the patients receiving IL-1Ra (p < 0.05) and inversely correlated (p < 0.001) with either TNF-alpha (r = -0.71) or IL-1 beta induction (r = -0.67) at admission. Conclusion: Treatment with IL-1Ra reverses peripheral innate immune suppression in the acute phase of stroke, which is associated with attenuated cortisol production. The mechanisms underlying these observations, including the potential impact of IL-1Ra on stroke severity and the clinical significance of immune suppression, require further evaluation in larger studies. (C) 2012 Elsevier Ltd. All rights reserved.